Looking for someone to take me down on this and show me risks I may not appreciate. I’m a holder but at current prices I’m looking at a bigger play.
Positives:
- A known safety profile
- An application without directed, tolerable therapy in IIH
- It seems to work (phase 2 data), off label access testiments
- Only drug I’m aware of to directly reduce CSF production - ie. different mechanism to mannitol, diamox, DECRA
- Likely an adjuvant therapy for CVA, mass lesions, ICH. Maybe others I’m not aware of. Addressable market for all is significant.
- The stock market I believe is not pricing the risk reward appropriately sub $1.
- It’s funded for the future studies, toxicokinetics I think. Lower likelihood of further capital raises.
Risks:
- Changing of formula to adjust to slow release. This poses risk however, it’s been done over and over for direct insulin formulations so possibly not as bigger deal as I see it?
- Delays in studies and further clarification / studies needed by FDA/EMA.
- Phase III not extrapolating the phase 2 data or adverse events - lower likely hood of ADRs given how long this has been used for.
- Competitors I’m not aware of being developed? I’ve some insights into the medicine world and the gap in market for Exenatide for this use, but I may not appreciate other products in development.
It’s my take that the risk reward is skewed favourably. Biotech is a binary outcome, bang or bust. I’ve tried to see where this will fall over but I see it as a very good play albeit the share price will oscillate at low levels for another 12 months I think.
All my opinion only.
Love to hear insights on the above....
- Forums
- ASX - By Stock
- IXC
- My take on things - Invex IXC
My take on things - Invex IXC
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.1¢ |
Change
0.001(1.43%) |
Mkt cap ! $5.335M |
Open | High | Low | Value | Volume |
7.1¢ | 7.3¢ | 7.1¢ | $2.546K | 35.86K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 14158 | 7.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 14158 | 0.071 |
1 | 62163 | 0.070 |
1 | 100000 | 0.063 |
1 | 100000 | 0.062 |
1 | 100000 | 0.061 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 5000 | 1 |
0.082 | 49683 | 1 |
0.083 | 4000 | 1 |
0.085 | 1000 | 1 |
0.090 | 126146 | 1 |
Last trade - 14.37pm 31/07/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online